The wounds were self-treated at home with several "burn ointments" for four days. On admission the burned area was covered with a greenish-yellow adherent eschar.

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns. Triggers $7.5 million milestone payment from Vericel ...

The product selectively removes burn eschar within 4 hours without harming surrounding ... The estimated median time to 95% or greater wound closure was 31 days for the NexoBrid arm and 36 days ...

The product selectively removes burn eschar within 4 hours without harming surrounding viable tissue. The approval was based on data from 2 clinical trials (ClinicalTrials.gov Identifier ...

Results from DETECT, the phase 3 study that supported the FDA approval of NexoBrid for the treatment of severe thermal burns, was recently published in the Journal of Burn Care & Research, Vericel ...

The company’s FDA-approved biologic, NexoBrid ®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., ... About the Wound Healing Society (WHS) ...

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; ...

Nexobrid (concentrate of proteolytic enzymes enriched in bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with ...